Navigation Links
Non-drug techniques reduce pain in hospitalized patients
Date:3/5/2010

Non-traditional therapies relieve pain among a wide range of hospitalized patients as much as 50 percent, according to a first-of-a-kind study in the Journal of Patient Safety.

The study shows that an inpatient integrative medicine program can have a significant impact on pain in an environment where pain management continues to be a major challenge, and traditional medications can have negative consequences.

"Roughly 80 percent of patients report moderate to severe pain levels after surgery," says Gregory Plotnikoff, M.D., one of the study's authors and medical director of the Penny George Institute for Health and Healing at Abbott Northwestern Hospital.

"We struggle to provide effective pain control while trying to avoid the adverse effects of opioid medications, such as respiratory depression, nausea, constipation, dizziness and falls."

The study included 1,837 cardiovascular, medical, surgical, orthopedics, spine, rehabilitation, oncology, and women's health patients at Abbott Northwestern between January 1, 2008, and June 30, 2009. They scored their pain verbally on a zero-to-ten scale before and after treatments.

The treatments included non-pharmaceutical services: mind body therapies to elicit the relaxation response, acupuncture, acupressure, massage therapy, healing touch, music therapy, aromatherapy, and reflexology.

The study, "The Impact of Integrative Medicine on Pain Management in a Tertiary Care Hospital" was published March 5 in the Journal of Patient Safety.

"Earlier studies narrowly focused on whether specific integrative therapies manage pain in either cancer or surgical patients," says Jeffery A. Dusek, Ph.D., research director for the George Institute.

"Our real-world study broadly shows that these therapies effectively reduce pain by over 50 percent across numerous patient populations. Furthermore, they can be clinically implemented in real time, across, and under the operation
'/>"/>

Contact: Gloria O'Connell
gloria.oconnell@allina.com
612-863-4801
Allina Hospitals & Clinics
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Treating Complicated Grief -- New NIMH Study Seeks 200 Older Adults Suffering from Unrelenting Symptoms of Complicated Grief for Participation in Non-Drug Clinical Trial
2. Non-drug treatment of Alzheimers disease: Long-term benefit not proven
3. New therapy based on magnetic stimulation shows promise for non-drug treatment for migraine
4. ADHD Treatment Guide: How to Safely, Effectively Use Medications and Non-Drug Therapies to Treat Attention Deficit Disorder
5. New Alzheimers Prevention Efforts, and Non-Drug Treatments, Featured at 25th Conference of Alzheimers Disease International
6. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
7. Exploring the Use of Techniques From Neuroscience in Todays Marketing
8. MRI techniques evolving towards better assessment of liver fibrosis
9. Improved diagnosis of cutaneous leishmaniasis thanks to new techniques
10. New Technology and Improved Techniques Arm Dermatologists With Tools to Minimize Facial Scars From Skin Cancer Surgery
11. Biopsy techniques have made PSA test less predictive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... How well patients recover from cancer surgery may ... and the operations themselves. Family conflicts and other ... complications, a Mayo Clinic study has found. Addressing ... patients, stress, speed their recoveries and save health ... looked at colon cancer patients, and found that ...
(Date:9/2/2014)... suggests that the key to more youthful immune function ... report published in the Journal of Leukocyte ... lungs of old mice had different responses to ... these changes were reversed by ibuprofen. , "Inflammation in ... said Joanne Turner, Ph.D., a researcher involved in the ...
(Date:9/2/2014)... 02, 2014 According to a ... the leading global authority in medical device market ... is expected to grow to over €2 billion ... increase in the number of procedures for the ... This market includes TURP devices, laser BPH devices, ...
(Date:9/2/2014)... 02, 2014 Nanomedicine is essentially ... diagnosing, treating and/or prevention of diseases and infections. ... cardiovascular, neurological, and oncology diseases. , Nanomedicine ... to various nanoparticles, their medical usages, and their ... considerable scope for research in this domain, and ...
(Date:9/2/2014)... On Saturday, September 6, 2014, The Concilio will present ... vida! Get Up! Get Moving!®. This event promotes Hispanic family ... for people of all ages and all sizes. The event, ... held at Kiest Park Recreation Center, 3080 S. Hampton Road, ... “Since 2007, we have partnered with National Alliance for Hispanic ...
Breaking Medicine News(10 mins):Health News:Family conflicts, other non-physical worries before cancer surgery raise patients' complication risk 2Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 2Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 3Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 2Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4
... Will Continue to be Used in Early ... from Decision Resources, WALTHAM, Mass., Oct. ... leading research and advisory firms focusing on ... is currently the leading biologic for Crohn,s ...
... 1, 2008 at this year,s liver ... SAN FRANCISCO, Oct. 27 Researchers analyzed 43,497,patients ... 22,863 adults,who received transplantation to determine the best time ... caused by differences in donor type was vastly offset ...
... 27 ReachMD XM 157 announces a new,"Medical ... receptor,antagonist and its effects on management of euvolemic ... XM 157, the first and only network for ... the Tide Against,Hyponatremia" four times a day October ...
... NORWALK, Conn., Oct. 27 Maclaren USA Inc.,announces the ... Chief Operation Officer., "Maclaren,s growth has been extraordinary ... our new from-birth transport system, the Grand Tour(TM),LX, is ... proven themselves to be exceptional leaders in their field. ...
... has donated a portable Automatic External Defibrillator (AED) to Habitat ... ... Newtown, Pennsylvania (PRWEB) October 27, 2008 -- HeartSine Technologies, ... donated a portable Automatic External Defibrillator (AED) to Habitat for ...
... reduced inflammation, cholesterol and belly fat , , SUNDAY, Oct. ... diet." , New research ties eating tart cherries ... weight and fat -- all major risk factors for ... presented by University of Michigan researchers at the American ...
Cached Medicine News:Health News:Humira to Replace Remicade as First Choice Among Biologics for the Treatment of Crohn's Disease 2Health News:Humira to Replace Remicade as First Choice Among Biologics for the Treatment of Crohn's Disease 3Health News:Early Liver Transplantation Regardless of Donor Type Increases Long-term Survival 2Health News:ReachMD XM 157 Announces Medical Information Feature on Treatment Options for Management of Hyponatremia 2Health News:ReachMD XM 157 Announces Medical Information Feature on Treatment Options for Management of Hyponatremia 3Health News:Maclaren Appoints New President and New Chief Operation Officer 2Health News:HeartSine Portable Defibrillator Donation Brings Added Safety to Habitat for Humanity of Charlotte ReStore Location 2Health News:Cherry-Enriched Diet Cut Heart Risks in Rats 2
(Date:9/2/2014)... -- Actavis plc (NYSE: ACT ) today ... has accepted for filing Actavis, New Drug Application (NDA) ... diarrhea and abdominal pain in men and women with ... eluxadoline has been granted priority review status by the ... "The NDA filing of eluxadoline marks an important ...
(Date:9/2/2014)... CITY, Calif. , Sept. 2, 2014  Abaxis, ... company manufacturing point-of-care blood instrumentation and consumables to the ... Clint Severson , Chairman and Chief Executive Officer, will ... Wednesday, September 10, 2014 at 10:20 a.m. ET. The ... York in New York City . ...
(Date:9/2/2014)... SAN DIEGO , Sept. 2, 2014   Mast Therapeutics, ... Executive Officer, Brian M. Culley , will present at the ... Tuesday, September 9, 2014 at 2:55 p.m. Eastern time in the ... New York . Interested parties can ... Therapeutics web site at www.masttherapeutics.com . An archived presentation will ...
Breaking Medicine Technology:Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 2Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 3Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 4Abaxis, Inc. to Present at the Morgan Stanley Global Healthcare Conference 2Mast Therapeutics To Present At The Rodman And Renshaw 16th Annual Global Investment Conference On September 9th 2Mast Therapeutics To Present At The Rodman And Renshaw 16th Annual Global Investment Conference On September 9th 3
... , WASHINGTON, Dec. 14 ... counsel on global and domestic communications and issues management, ... PositiveID Corporation (Nasdaq: PSID ) to serve as ... will conduct media relations for PositiveID,s corporate communications and ...
... , NEW HAVEN, Conn., ,Dec. 14 /PRNewswire-FirstCall/ ... today announced that it had received a complete response ... related to its New Drug Application ("NDA") for Onrigin(TM) ... indicates that the FDA cannot approve the Company,s NDA ...
Cached Medicine Technology:Gibraltar Associates Named Agency of Record for Health Information and Diagnostic Provider PositiveID Corporation 2Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration 2Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: